Skip to content
DataLookout
Menu

NCT05165446

Novel MRE Technique to Assess a Risk Factor for Liver Cancer

StatusActive, Not Recruiting
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 7 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 36 words
    • Study completion pushed from Aug 30, 2026 to Jan 30, 2027
  2. Minor Study completion date: Sep 30, 2025 to Aug 30, 2026v8
  3. Minor Primary completion date changed from estimate of Jan 2024 to Jan 1, 2024
    • Study completion date: Mar 2024 to Sep 30, 2025
    v7
  4. Notable Primary completion date: Mar 2023 to Jan 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Mar 2023 to Mar 2024
    • Site details revised
    v5
  5. Minor Primary and study completion dates: Jan 2023 to Mar 2023
    • Site contact updated
    v4
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 2022 to Jan 27, 2022
    v3
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Novel MRE technique to assess tissue viscoelasticity as a risk factor for liver cancer
Timeframe: For individual patients: duration of the study 8 weeks (including lab, scheduling the MR and 4w post MR period).

Secondary (1)

Studies on liver injury and glycemic control.

Sites

1 site in 1 country

  • Stanford HospitalStanford, California, United States